CDK4/6 Inhibitors Archives

Novartis’ Kisqali Offers More Life for Breast Cancer Patients

Advanced Breast Cancer, Blockbusters, CDK4/6 Inhibitors, Chemotherapy, Clinical Trials, Novartis, Overall Survival (OS), Postmenopausal, R&D, Therapeutics

Novartis announced positive news for patients with metastatic breast cancer. New data showed Kisqali (ribociclib), in combination with the chemotherapy drug fulvestrant, added nearly 16 months of survival benefit to the lives of patients compared to fulvestrant alone.

May 4, 2022/by BioSpace

Lilly’s Verzenio Hits Mark in High-Risk Breast Cancer Patients

Breast Cancer, CDK4/6 Inhibitors, Clinical Trials, Endocrine Therapy, High-Risk Breast Cancer, Primary Endpoints, R&D, Therapeutics

In a Phase III study, Eli Lilly’s Verzenio (abemaciclib) combined with standard adjuvant endocrine therapy met the trial’s primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.

June 16, 2020/by BioSpace